Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.43 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
| ▸ | CCNH | P51946 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665584 | 0.90 | HTR6 (0.48) | EGFRMAPT | |
| SCHEMBL18074115 | 0.88 | CDK7 (0.43) | EGFRCDK7CCNHCCNT1CDK9 | |
| SCHEMBL18074116 | 0.81 | CDK9 (0.48) | EGFRCDK7CCNHCCNT1CDK9 | |
| SCHEMBL16665634 | 0.79 | HTR6 (0.50) | EGFR | |
| SCHEMBL18074117 | 0.74 | TSHR (0.44) | EGFRCDK7CCNHMAPTNPSR1 | |
| SCHEMBL16655389 | 0.71 | EGFR (0.48) | EGFRCCNT1CDK9 | |
| SCHEMBL18074097 | 0.70 | CDK7 (0.56) | EGFRCDK7CCNHCCNT1CDK9 | |
| SCHEMBL17373137 | 0.68 | EGFR (0.55) | EGFR | |
| SCHEMBL14661011 | 0.67 | EGFR (0.55) | EGFR | |
| SCHEMBL18069822 | 0.67 | CDK7 (0.54) | EGFRCDK7CCNHCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | EGFR 3410/4885CDK7 1/4885CCNH 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.